Early prediction of cisplatin nephrotoxicity in head and neck cancer patients - an evaluation with urinary biomarkers

U. V. Saleena, K. Nalini, K. Gopalakrishna, R. Prabhu, B. M. Vadhiraja, M. S. Athiyamaan, Asha Kamath, Vidyasagar S Mamidipudi

Research output: Contribution to journalArticle

Abstract

Background: Nephrotoxic Acute Kidney Injury (AKI) is a common condition associated with considerable morbidity and mortality. Acute exposure to potentially nephrotoxic drugs requires early appraisal of the extent of renal injury to determine the need for specific interventions. Hence this study was designed to evaluate two urinary biomarkers for the early diagnosis of AKI due to cisplatin chemotherapy, including Neutrophil gelatinase-associated lipocalin (uNGAL) and Cystatin C (uCysC). Methods: Urinary biomarker levels in cisplatin treated cancer patients were estimated before and at 2hrs, 6hrs, 12hrs, 24hrs and 48hrs after cisplatin administration. Diagnostic performances of biomarkers were studied by ROC analysis with AUC and predictive values. Results: uNGAL was identified as the earlier biomarker of AKI induced by cisplatin as it detected kidney injury as early as 2hrs after the exposure of nephrotoxic drug with an AUC of 0.8, which is 46hrs before the elevation of serum creatinine. uCysC detected AKI 6hrs after cisplatin administration with AUC 0.73. Conclusion: Indication of AKI by biomarker elevations can provide an early warning signal which may have implications in therapy by either stopping the nephrotoxic drug or reducing its dose or even by substituting it with a less nephrotoxic one. The research in this direction should focus on evolving rapid procedures with an eventual point-of-care test for urinary biomarker determinations that will transform the scope of biomarkers significantly in the field of early renal injury.

Original languageEnglish
Pages (from-to)2893-2901
Number of pages9
JournalInternational Journal of Pharmaceutical Sciences and Research
Volume6
Issue number7
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Head and Neck Neoplasms
Cisplatin
Biomarkers
Acute Kidney Injury
Area Under Curve
Cystatin C
Kidney
Wounds and Injuries
Point-of-Care Systems
Pharmaceutical Preparations
ROC Curve
Early Diagnosis
Creatinine
Morbidity
Drug Therapy
Mortality
Serum
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{b15d5feacfaf4a3aac7890b05af392b3,
title = "Early prediction of cisplatin nephrotoxicity in head and neck cancer patients - an evaluation with urinary biomarkers",
abstract = "Background: Nephrotoxic Acute Kidney Injury (AKI) is a common condition associated with considerable morbidity and mortality. Acute exposure to potentially nephrotoxic drugs requires early appraisal of the extent of renal injury to determine the need for specific interventions. Hence this study was designed to evaluate two urinary biomarkers for the early diagnosis of AKI due to cisplatin chemotherapy, including Neutrophil gelatinase-associated lipocalin (uNGAL) and Cystatin C (uCysC). Methods: Urinary biomarker levels in cisplatin treated cancer patients were estimated before and at 2hrs, 6hrs, 12hrs, 24hrs and 48hrs after cisplatin administration. Diagnostic performances of biomarkers were studied by ROC analysis with AUC and predictive values. Results: uNGAL was identified as the earlier biomarker of AKI induced by cisplatin as it detected kidney injury as early as 2hrs after the exposure of nephrotoxic drug with an AUC of 0.8, which is 46hrs before the elevation of serum creatinine. uCysC detected AKI 6hrs after cisplatin administration with AUC 0.73. Conclusion: Indication of AKI by biomarker elevations can provide an early warning signal which may have implications in therapy by either stopping the nephrotoxic drug or reducing its dose or even by substituting it with a less nephrotoxic one. The research in this direction should focus on evolving rapid procedures with an eventual point-of-care test for urinary biomarker determinations that will transform the scope of biomarkers significantly in the field of early renal injury.",
author = "Saleena, {U. V.} and K. Nalini and K. Gopalakrishna and R. Prabhu and Vadhiraja, {B. M.} and Athiyamaan, {M. S.} and Asha Kamath and Mamidipudi, {Vidyasagar S}",
year = "2015",
month = "1",
day = "1",
doi = "10.13040/IJPSR.0975-8232.6(7).2893-01",
language = "English",
volume = "6",
pages = "2893--2901",
journal = "International Journal of Pharmaceutical Sciences and Research",
issn = "2320-5148",
publisher = "Society of Pharmaceutical Sciences and Research",
number = "7",

}

Early prediction of cisplatin nephrotoxicity in head and neck cancer patients - an evaluation with urinary biomarkers. / Saleena, U. V.; Nalini, K.; Gopalakrishna, K.; Prabhu, R.; Vadhiraja, B. M.; Athiyamaan, M. S.; Kamath, Asha; Mamidipudi, Vidyasagar S.

In: International Journal of Pharmaceutical Sciences and Research, Vol. 6, No. 7, 01.01.2015, p. 2893-2901.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early prediction of cisplatin nephrotoxicity in head and neck cancer patients - an evaluation with urinary biomarkers

AU - Saleena, U. V.

AU - Nalini, K.

AU - Gopalakrishna, K.

AU - Prabhu, R.

AU - Vadhiraja, B. M.

AU - Athiyamaan, M. S.

AU - Kamath, Asha

AU - Mamidipudi, Vidyasagar S

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Nephrotoxic Acute Kidney Injury (AKI) is a common condition associated with considerable morbidity and mortality. Acute exposure to potentially nephrotoxic drugs requires early appraisal of the extent of renal injury to determine the need for specific interventions. Hence this study was designed to evaluate two urinary biomarkers for the early diagnosis of AKI due to cisplatin chemotherapy, including Neutrophil gelatinase-associated lipocalin (uNGAL) and Cystatin C (uCysC). Methods: Urinary biomarker levels in cisplatin treated cancer patients were estimated before and at 2hrs, 6hrs, 12hrs, 24hrs and 48hrs after cisplatin administration. Diagnostic performances of biomarkers were studied by ROC analysis with AUC and predictive values. Results: uNGAL was identified as the earlier biomarker of AKI induced by cisplatin as it detected kidney injury as early as 2hrs after the exposure of nephrotoxic drug with an AUC of 0.8, which is 46hrs before the elevation of serum creatinine. uCysC detected AKI 6hrs after cisplatin administration with AUC 0.73. Conclusion: Indication of AKI by biomarker elevations can provide an early warning signal which may have implications in therapy by either stopping the nephrotoxic drug or reducing its dose or even by substituting it with a less nephrotoxic one. The research in this direction should focus on evolving rapid procedures with an eventual point-of-care test for urinary biomarker determinations that will transform the scope of biomarkers significantly in the field of early renal injury.

AB - Background: Nephrotoxic Acute Kidney Injury (AKI) is a common condition associated with considerable morbidity and mortality. Acute exposure to potentially nephrotoxic drugs requires early appraisal of the extent of renal injury to determine the need for specific interventions. Hence this study was designed to evaluate two urinary biomarkers for the early diagnosis of AKI due to cisplatin chemotherapy, including Neutrophil gelatinase-associated lipocalin (uNGAL) and Cystatin C (uCysC). Methods: Urinary biomarker levels in cisplatin treated cancer patients were estimated before and at 2hrs, 6hrs, 12hrs, 24hrs and 48hrs after cisplatin administration. Diagnostic performances of biomarkers were studied by ROC analysis with AUC and predictive values. Results: uNGAL was identified as the earlier biomarker of AKI induced by cisplatin as it detected kidney injury as early as 2hrs after the exposure of nephrotoxic drug with an AUC of 0.8, which is 46hrs before the elevation of serum creatinine. uCysC detected AKI 6hrs after cisplatin administration with AUC 0.73. Conclusion: Indication of AKI by biomarker elevations can provide an early warning signal which may have implications in therapy by either stopping the nephrotoxic drug or reducing its dose or even by substituting it with a less nephrotoxic one. The research in this direction should focus on evolving rapid procedures with an eventual point-of-care test for urinary biomarker determinations that will transform the scope of biomarkers significantly in the field of early renal injury.

UR - http://www.scopus.com/inward/record.url?scp=85042581263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042581263&partnerID=8YFLogxK

U2 - 10.13040/IJPSR.0975-8232.6(7).2893-01

DO - 10.13040/IJPSR.0975-8232.6(7).2893-01

M3 - Article

VL - 6

SP - 2893

EP - 2901

JO - International Journal of Pharmaceutical Sciences and Research

JF - International Journal of Pharmaceutical Sciences and Research

SN - 2320-5148

IS - 7

ER -